Abstract
Cerebral venous thrombosis (CVT) is a rare type of stroke that carries a risk of recurrence, including conditions such as limb venous thrombosis and pulmonary thrombosis… A cross-sectional study conducted at Bach Mai Hospital from January 2022 to June 2024 evaluated the safety and efficacy of oral anticoagulants, including direct oral anticoagulants (DOAC) and warfarin, in 47 patients diagnosed with cerebral venous thrombosis. The study found that the average age of the participants was 44.7 ± 16.8 years. The complete recanalization rates for the groups using DOAC and warfarin were 80.5% and 66.7%, respectively. Additionally, the proportion of patients achieving a favorable recovery, indicated by an mRS score of 0-1, was 80.5% for the DOAC group and 83.3% for the warfarin group. Importantly, the rates of recurrent venous thrombosis and bleeding events were low, at 2.4% and 4.9%, respectively. This study provides valuable information regarding the efficacy and safety of both DOAC and warfarin for patients with CVT, aiding clinicians in making informed decisions about anticoagulant therapy.